 |
  |
 |
|
 |
 |
Press Releases
- ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 Drug Represents Potential New Approach for the Treatment of Inflammatory Disease May 13, 2008
[ HTML | PDF ]
- ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors January 17, 2008
[ HTML | PDF ]
- ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth September 26, 2007
[ HTML | PDF ]
- ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for Nomination of CCR1 Small Molecule Development Candidate July 24, 2007
[ HTML | PDF ]
- ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN™ in Crohn's Disease at the Digestive Disease Week 2007 Conference May 23, 2007
[ HTML | PDF ]
- ChemoCentryx's Traficet-EN™ Phase 2 Data in Crohn's Disease Accepted for Oral Presentation and Highlighted in "Best of UEGW" Session at DDW 2007 May 17, 2007
[ HTML | PDF ]
- ChemoCentryx Appoints Juan Jaen, Ph.D., Senior Vice President, Drug Discovery January 4, 2007
[ HTML | PDF ]
- ChemoCentryx Presents Clinical and Preclinical Data on Traficet-EN™ in
Inflammatory Bowel Disease (IBD) December 1, 2006
[ HTML | PDF ]
- ChemoCentryx Reports Promising Clinical Activity for Traficet-EN™ from Phase 2 Trial for the Treatment of Crohn's Disease October 24, 2006
[ HTML | PDF ]
- GlaxoSmithKline and ChemoCentryx Enter Into Drug Discovery and Development Alliance in Inflammatory Disorders August 24, 2006
[ HTML | PDF ]
- ChemoCentryx Completes Series C Financing August 24, 2006
[ HTML | PDF ]
- ChemoCentryx Names Regina E. Herzlinger to the Company's Board of Directors February 7, 2006
[ HTML | PDF ]
- ChemoCentryx Announces Key Senior Management Team Additions
January 5, 2006
[ HTML | PDF ]
- ChemoCentryx to Initiate Clinical Studies of CCR2 Antagonist CCX915 November 22, 2005
[ HTML | PDF ]
- ChemoCentryx Presents Positive Results from Phase 1 Clinical Studies of Traficet-EN™ at Digestive Disease Week Meeting May 16, 2005
[ HTML | PDF ]
- ChemoCentryx Initiates Phase II Clinical Trial of Traficet-EN™ in Inflammatory Bowel Disease January 6, 2005
[ HTML | PDF ]
- ChemoCentryx Raises $33 Million in Private Financing June 17, 2004
[ HTML | PDF ]
- ChemoCentryx and Forest Laboratories to Collaborate on the Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics March 15, 2004
[ HTML | PDF ]
- ChemoCentryx Begins Phase I Clinical Trial of Traficet-EN™, a Novel Drug Candidate for the Treatment of Inflammatory Bowel Disease January 13, 2004
[ HTML | PDF ]
- ChemoCentryx Awarded $14 Million NIH Grant to Develop Chemokine-Based Immunomodulators October 13, 2003
[ HTML | PDF ]
- ChemoCentryx Announces Initiation of Phase I Clinical Trial by Tularik September 17, 2002
[ HTML | PDF ]
|
|
 |
 |
 |
|
 |